Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction

医学 沙库比林、缬沙坦 缬沙坦 射血分数 心脏病学 沙库比林 心力衰竭 内科学 血压
作者
Alberto Foà,Muthiah Vaduganathan,Brian Claggett,Maria Pabón,Henri Lu,Marc A. Pfeffer,Milton Packer,Orly Vardeny,Jean L. Rouleau,Martin Lefkowitz,Robert J. Mentz,Pardeep S. Jhund,Akshay S. Desai,John J.V. McMurray,Scott D. Solomon
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:83 (18): 1731-1739 被引量:12
标识
DOI:10.1016/j.jacc.2024.02.035
摘要

Hypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in HFmrEF and HFpEF. We investigated predictors of treatment-associated hypotension, clinical outcomes after hypotension, and the relationship between LVEF and incidence of hypotension in the PARAGON-HF trial. PARAGON-HF randomized patients with chronic HF (≥45%) to sacubitril/valsartan or valsartan. Following randomization, hypotension was defined as investigator-reported hypotension with a SBP <100 mmHg. Predictors of hypotension were assessed using multivariable Cox models. Associations between hypotension and clinical outcomes were evaluated in time-updated Cox models. The relationship between treatment, LVEF, and incident rates of hypotension and clinical outcomes was estimated using Poisson regression models. Of 4,796 patients in PARAGON-HF, 637 (13%) experienced hypotension, more frequently in the sacubitril/valsartan arm (p<0.001). Following documented hypotension, patients had higher risk of CV death and total HF hospitalizations (adjusted RR 1.63; CI 1.27-2.09; p<0.001) and all-cause death (adjusted HR 1.62; CI 1.28-2.05; p<0.001). LVEF modified the association between sacubitril/valsartan and risk of hypotension (Pinteraction=0.019) such that patients with LVEF≥60% experienced substantially higher treatment-related risks of hypotension. In PARAGON-HF, a higher LVEF was associated with an increased risk of hypotension in patients treated with sacubitril/valsartan compared with valsartan. Since these subjects are also less likely to derive clinical benefit from sacubitril/valsartan, our data reinforce that the benefit/risk ratio favors the use of sacubitril/valsartan in patients with LVEF below normal, but not at higher LVEF.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
飒飒给飒飒的求助进行了留言
刚刚
2023204306324完成签到,获得积分20
刚刚
依灵完成签到,获得积分10
2秒前
香蕉觅云应助7733采纳,获得10
2秒前
5秒前
小猪完成签到,获得积分10
5秒前
7秒前
萌面大侠完成签到,获得积分10
7秒前
7秒前
金枪鱼完成签到,获得积分10
8秒前
sssssssssss完成签到,获得积分10
8秒前
mary发布了新的文献求助10
10秒前
研友_VZG7GZ应助hahaha123213123采纳,获得10
10秒前
枕星发布了新的文献求助10
12秒前
12秒前
13秒前
13秒前
求求大家了完成签到,获得积分10
13秒前
阳光完成签到,获得积分10
13秒前
Crystal完成签到 ,获得积分10
15秒前
16秒前
16秒前
17秒前
17秒前
17秒前
乐乐应助赖道之采纳,获得10
18秒前
18秒前
Sun_Chen完成签到,获得积分10
18秒前
体贴凌柏发布了新的文献求助10
19秒前
成就的笑南完成签到 ,获得积分10
19秒前
20秒前
20秒前
wyw123完成签到,获得积分10
20秒前
求大佬帮助完成签到,获得积分10
20秒前
李健的小迷弟应助zyq采纳,获得10
21秒前
陈隆完成签到,获得积分10
21秒前
哎呀完成签到 ,获得积分10
21秒前
量子星尘发布了新的文献求助10
22秒前
mary完成签到,获得积分10
22秒前
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029